Regulacje i polityka gospodarcza · 21/09/1995
Bristol Myers Squibb Seeks Extension of Exclusive Patent License for Opdivo
Bristol Myers Squibb has submitted a notice to the U.S. Patent and Trademark Office requesting a prospective extension of its exclusive patent license for Opdivo, a cancer treatment medication.
Original source language: Federal Register — All DocumentsOpen original release →